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NIH-USA official definition: 
A characteristic that is objectively measured and evaluated as 
indicator of normal  or pathogenic biological processes or
pharmacological response to a therapeutic intervention”
Biomarker still needed for
• early detection of diseases to benefit from the potential 
therapies. 
• pharmacodynamic assessment of drug action to help guide dose 
and schedule
• selection of patients who will benefit from therapy 
(pharmacoproteomics)
impact on patient well being and financial viability of healthcare systems 
• Abnormalies in the production or function of 
the proteins are linked to health, 
environmental response and many diseases
• Protein is the main target of many therapeutic
Why Protein as Biomarker ? 
To understand how to control an 
environmenta  resp nse and or treat
a particular disease, it is necessary to 
identify t  proteins associated with 
drugs
“Proteins are two steps closer than genes to 
most biological phenomena and diseases”
Hood et al Proteomics. 2012 Sep;12(18):2773-83 
these processes and understand how 
they function.
Clinical Proteomics
Dedicated to the study of the PROTEOME 
PROFILE associated with the HEALTHY AND 
DISEASE STATE, in the search for 
DIAGNOSTIC / PROGNOSTIC / MONITORING 
BIOMARKERS or as TARGETS for the 
development of new therapeutic approaches
Proteins are complex
Genes are digital in nature with a 4-letter language, proteins are analog with a 20
letters language; genes operate in a one-dimensional world and proteins in a three-
dimensional world
Proteins is extremely complex due to: modifications by gene mutation, RNA editing,
RNA splicing, up to 400 types of covalent changes and protein processing
Proteins are dynamical, changing their 3-dimensional structures, positions in the
cell, concentrations at different cellular sites, sequences, covalent chemistries, and
interactions with other proteins and molecules of many types in response to
endogenous and exogenous stimuli;
Proteins exhibit a 106 dynamic range in tissues and a 1012 dynamic range in blood,
making quantification essential
Proteins lack the molecular complementarity of DNA and hence cannot be amplified
prior to measurement—thus, higher ultrasensitive techniques to measure and
analyze protein molecules is needed
Hood et al Proteomics. 2012 Sep;12(18):2773-83 
• Discovery-based approach
Proteomics Technology
• Targeted –based approach
Discovery -based approach
What proteins can be
detected in this sample ? 
Discovery Phase Validation/Translation Phase
Penque, Expert Rev Proteomics, 2007, 4:199-209

























Is protein X measurable in this sample?
Shotgun proteomics
Biochemical experiments
Antibody /Affinity - based
http://www.proteinatlas.org/







(170,000SRM assays for human)
Literature
The balance between scope/sensitivity/scalability of discovery and targeted proteomics.
Due to the broad-scope nature and sensitivity of discovery proteomics, the ability to 
perform a comprehensive analysis of hundreds or thousands of samples is limited. 
Conversely, targeted proteomic analysis entails the quantitation of discrete subsets of 
peptides, which allows the ability to analyze these peptides across thousands of samples 
with the highest level of sensitivity.
Quantitative Proteomics
Protein abundance and sample 
complexity are significant factors that 
affect the availability of proteins for 
mass spectrometric quantitation
R e l a t i v e
A b s o l u t e /  
Q u a n t i t a t i o nP r o t e o m i c s
Proteomics Clinical Purposes
(some examples)
Laboratório de Proteómica 
Departamento de Genética Humana
Unidade de Tecnologia & Inovação
INSA, I.P. Ricardo Jorge-Lisboa
Missões
Desenvolver uma plat forma I&D inovadora baseada na 
proteómica para valid ção, implementação de 
biomarcadores já existentes ou descoberta de novos 
Investigação Serviços Outras Actividades
Missão
biomarcadores de diagnóstico, prognóstico e 
monitorização de doenças ou como alvos a novos 
abordagens terapêuticas. 
Prestar colaboração e serviços de caracterização de 
proteínas pela proteómica 
Contribuir para o desenvolvimento da proteómica no nosso 
país (promoção/realização de cursos/estágios/conferências, 
networking) na área da proteómica
Running Projects
1. Proteomics of chronic lung diseases leading to biomarkers and 
therapeutic target discovery. FCT project POCTI/SAU-
MMO/56163/2004. PI: D Penque
2. Environmental Tobacco Smoke Exposure at Portuguese 
Restaurants, Bars and nightclubs: health effects and early 
molecular mechanisms underlying respiratory disorders. 
Research 
FCG/ACSS. PI: T Simões & D Penque.
3. MSIA technology development . PI: D Penque & V Torres
4. Obstructive sleep apnea and associated metabolic/cardiovascular 
disorders: understanding mechanisms towards early diagnosis and 





Biormaker Discovery of Chronic Lung Diseases 
D Penque Expert Rev. Proteomics 4 (2) 2007 
 Basic mechanism responsible for 
F508del-CFTR retention in ER 

















Investigating by Proteomics the trafficking
defect of F508del-CFTR






























































BHK cells stably expressing CFTR  
Progenesis PG200v2006
BHK cell line 























































































































6 groups (cell types/conditions)
4-5 gels/group
ANOVA, p < 0.05
Normalized volume



























































139 protein spots differentially 
expressed
125 proteins spots identified
Differences over 1.5













Maturation and traff icking
Other
Several degradation associated proteins were down-regulated, while BiP and other 
UPR related proteins were found up-regulated in BHK-F508del cells under the CFTR-
“rescue” treatment at low temperature.
14%






















↑ BIP, mortalin, Hsp90, Hsp70





Expression Reversion of some 
proteins involved in CFTR 
maturation & trafficking   
e.g ↑ RACK1 









PALM Microscope 2000 lung epithelial cells





acid metabolism in the
abnormal responses of CF 
mutant
mice to injury.
Carvalho-Oliveira et al, 2009, JPR, 8:3606-16














Dysregulated Pathways (~70 p) : 
• abnormal tissue/airway remodeling,  
protease/antiprotease imbalance, innate
immune dysfunction, 
• chronic inflammation, 
• nutritional imbalance
• P. aeruginosa colonization. 
Apolipoproteins family (VDBP, ApoA-I, and ApoB) gradually 
lower expression from non-CF to CF-carrier individuals and 
from those to CF patients, 
The enzyme NDKB was identified only in the CF, its functions 
account for ion sensor in epithelial cells, pancreatic secretion, 
neutrophil-mediated inflammation and energy production, 
highlighting its physiological significance in the context of CF.

Most enriched Pathways : 
• cell-to-cell signaling and interaction
• hematological system
• development, 
• immune response, 
• oxidative stress and 
• cytoskeleton. 
• Chorein (VPS13A) > cell
COPD
membrane deformation of RBC c 
Methemoglobin reductase
• (Cytochrome CYB5R3) > COPD 
patients may be at higher risk for 
developing methemoglobinemia.





Obsructive Sleep Apnea is needed   
• to distinguish snoring from OSA , facilitating population 
screening and prevention of OSA-associated outcomes  
• to provide new insights into pathophysiological aspects 
of OSA that underlie the increased cardiovascular and 








































CANDITATES BIOMARKERS OF OSA 
VERIFICATION   PHASE


















76 spots identified differentially 
abundant  (Anova p≤ 0.05) 
30 spots identified by 
MALDITOTOF, corresponding






























































































































































































































Anova  p=0.009 Anova  p=0.002 Anova  3.8x10-6


































































































































































































continuous positive airway pressure (CPAP),


















V a l i d a t i o n P h a s e
Summary
Proteomics can provide:
• New insights into the poorly-understood
pathogenetic processes of diseases.
• New biomarkers for diagnosis & prognosis
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